Publicacións nas que colabora con Antonio Antela López (14)

2022

  1. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

2020

  1. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  2. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

  3. Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 12, pp. 3517-3524

2018

  1. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  2. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

  2. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

2014

  1. Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions

    PLoS ONE, Vol. 9, Núm. 12

  2. Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes

    International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6

2009

  1. Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality

    Current HIV Research, Vol. 7, Núm. 2, pp. 224-230